Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Publication
, Journal Article
Duda, DG; Willett, CG
Published in: Oncology (Williston Park)
August 2012
Duke Scholars
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
August 2012
Volume
26
Issue
8
Start / End Page
741 / 743
Location
United States
Related Subject Headings
- Rectal Neoplasms
- Preoperative Care
- Practice Guidelines as Topic
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Duda, D. G., & Willett, C. G. (2012). Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park), 26(8), 741–743.
Duda, Dan G., and Christopher G. Willett. “Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?” Oncology (Williston Park) 26, no. 8 (August 2012): 741–43.
Duda DG, Willett CG. Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park). 2012 Aug;26(8):741–3.
Duda, Dan G., and Christopher G. Willett. “Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?” Oncology (Williston Park), vol. 26, no. 8, Aug. 2012, pp. 741–43.
Duda DG, Willett CG. Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park). 2012 Aug;26(8):741–743.
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
August 2012
Volume
26
Issue
8
Start / End Page
741 / 743
Location
United States
Related Subject Headings
- Rectal Neoplasms
- Preoperative Care
- Practice Guidelines as Topic
- Humans